BEXIMCO PHARMA.GDR REGS 1 (R2WA) - Net Assets
Based on the latest financial reports, BEXIMCO PHARMA.GDR REGS 1 (R2WA) has net assets worth €53.63 Billion EUR (≈ $62.70 Billion USD) as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€73.80 Billion ≈ $86.28 Billion USD) and total liabilities (€20.17 Billion ≈ $23.58 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore BEXIMCO PHARMA.GDR REGS 1 (R2WA) cash conversion ratio to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €53.63 Billion |
| % of Total Assets | 72.67% |
| Annual Growth Rate | 11.57% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 5.56 |
BEXIMCO PHARMA.GDR REGS 1 - Net Assets Trend (2021–2024)
This chart illustrates how BEXIMCO PHARMA.GDR REGS 1's net assets have evolved over time, based on quarterly financial data. Also explore BEXIMCO PHARMA.GDR REGS 1 asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for BEXIMCO PHARMA.GDR REGS 1 (2021–2024)
The table below shows the annual net assets of BEXIMCO PHARMA.GDR REGS 1 from 2021 to 2024. For live valuation and market cap data, see BEXIMCO PHARMA.GDR REGS 1 stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | €51.90 Billion ≈ $60.68 Billion |
+8.99% |
| 2023-06-30 | €47.62 Billion ≈ $55.67 Billion |
+6.68% |
| 2022-06-30 | €44.64 Billion ≈ $52.18 Billion |
+19.46% |
| 2021-06-30 | €37.36 Billion ≈ $43.68 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BEXIMCO PHARMA.GDR REGS 1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 45.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €35.08 Billion | 73.16% |
| Other Components | €12.87 Billion | 26.84% |
| Total Equity | €47.95 Billion | 100.00% |
BEXIMCO PHARMA.GDR REGS 1 Competitors by Market Cap
The table below lists competitors of BEXIMCO PHARMA.GDR REGS 1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gunung Raja Paksi
JK:GGRP
|
$208.65 Million |
|
Lotte Data Communication Company
KO:286940
|
$208.65 Million |
|
Decora SA
WAR:DCR
|
$208.73 Million |
|
Investcorp Europe Acquisition I Corp
NASDAQ:IVCB
|
$208.74 Million |
|
Hi-Tech Pipes Limited
NSE:HITECH
|
$208.61 Million |
|
RAINBOW RARE EARTHS LTD
F:RR1
|
$208.51 Million |
|
Hinduja Global Solutions Limited
NSE:HGS
|
$208.33 Million |
|
Studsvik AB
ST:SVIK
|
$208.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BEXIMCO PHARMA.GDR REGS 1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 43,680,703,738 to 47,949,964,744, a change of 4,269,261,006 (9.8%).
- Net income of 5,829,529,200 contributed positively to equity growth.
- Dividend payments of 1,585,900,722 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €5.83 Billion | +12.16% |
| Dividends Paid | €1.59 Billion | -3.31% |
| Other Changes | €25.63 Million | +0.05% |
| Total Change | €- | 9.77% |
Book Value vs Market Value Analysis
This analysis compares BEXIMCO PHARMA.GDR REGS 1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | €83.01 | €0.40 | x |
| 2022-06-30 | €91.01 | €0.40 | x |
| 2023-06-30 | €97.91 | €0.40 | x |
| 2024-06-30 | €107.48 | €0.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BEXIMCO PHARMA.GDR REGS 1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.16%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.13%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 1.45x
- Recent ROE (12.16%) is below the historical average (12.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 13.85% | 17.39% | 0.56x | 1.41x | €1.42 Billion |
| 2022 | 12.62% | 14.78% | 0.52x | 1.63x | €1.06 Billion |
| 2023 | 10.56% | 11.75% | 0.57x | 1.58x | €246.00 Million |
| 2024 | 12.16% | 13.13% | 0.64x | 1.45x | €1.03 Billion |
Industry Comparison
This section compares BEXIMCO PHARMA.GDR REGS 1's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $6,058,012,174
- Average return on equity (ROE) among peers: -98.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BEXIMCO PHARMA.GDR REGS 1 (R2WA) | €53.63 Billion | 13.85% | 0.38x | $208.62 Million |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $54.11 Billion | 6.89% | 0.98x | $1.19 Billion |
| PEPTONIC MEDICAL (28L) | $75.32 Million | -56.54% | 0.42x | $4.14 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $5.95 Billion | 11.12% | 0.39x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $201.51 Million | -13.72% | 0.07x | $157.72 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-8.51 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $29.16 Million | -49.27% | 0.13x | $13.93 Million |
| EQL PHARMA AB (7JK) | $221.03 Million | 19.51% | 2.66x | $80.44 Million |
About BEXIMCO PHARMA.GDR REGS 1
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskelet… Read more